FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	burden										
hours per response	e· 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person* <u>Lippoldt Darin</u>				<u>N</u>	2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [ NBIX ]									(Che	eck a	tionship of Reportin all applicable) Director Officer (give title below) Chief Leg		10% O Other (		wner (specify	
(Last) (First) (Middle) 12780 EL CAMINO REAL					3. Date of Earliest Transaction (Month/Day/Year) 02/06/2024													gal C	below) Officer		
(Street) SAN DII	Street) SAN DIEGO CA 92130				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					on
(City)	(Si	ate) (2	Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a constitution satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction											uction or writ	ten pla	an that is inte	ended to		
		Table	۱-	Non-Deriva	tive	Secui	rities	Acq	uir	ed, [	Dis	posed	of, or	Bene	ficia	lly (	Owne	∍d			
Date				2. Transaction Date (Month/Day/Ye	Execution		Date, Tra		ansaction ode (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3,					5. Amount of Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Co	ode V		Am	ount	(A) or (D)			1		Reported Transaction(s) (Instr. 3 and 4)			
Common	Stock			02/06/2024	4		S		S <sup>(1)</sup>		1	,041	D	D \$142.166		63 <sup>(2)</sup> 37,939		7,939	D		
Common Stock 02/08/202				02/08/2024	1			S	S <sup>(3)</sup>			911	D	\$134	\$134.2359 <sup>(4)</sup>		38,755			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  1. Title of 2. 3. Transaction Date Securition Date Securition Date Securition Date Securition Date Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  1. Title of 2. Amount of Date Securition Date Securition Date Securition Date Securition Date Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
Derivative Security (Instr. 3)	rity or Exercise (Month/Day/Year) if any					Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)				Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Secui Instr	rity	derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Cod	le V	(A)	(D)	Date Exercisal		ble	Expiratio Date	n Titl	Amo or Num of Shar	ber	1					

## Explanation of Responses:

- 1. Sale of 1,041 shares of common stock issued upon vesting of 1,975 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (934) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$141.04 to \$143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. Sale of 911 shares of common stock issued upon vesting of 1,727 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (816) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$132.64 to \$136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

## Remarks:

/s/ Darin Lippoldt

02/08/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.